XGN - Exagen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.53
+0.54 (+3.86%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.99
Open13.86
Bid12.00 x 900
Ask15.01 x 900
Day's Range13.80 - 14.53
52 Week Range11.54 - 19.50
Volume31,274
Avg. Volume114,600
Market Cap174.866M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-293.37
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.50
Trade prices are not sourced from all markets
  • GlobeNewswire

    Exagen to Be Honored with National Research Innovation Award by Lupus Foundation of America

    Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that the Lupus Foundation of America will be recognizing their CEO Ron Rocca at the upcoming Evening of Hope Gala October 28. “We are humbled by this honor and grateful to the many internal and external clinical and scientific collaborators who contributed to the development of the AVISE® CTD panel,” said Ron Rocca, President and CEO of Exagen Inc. “We are closely aligned with the LFA in their mission to reduce the time to an accurate diagnosis of lupus, which is a key contributor to better control of the disease.  It is not acceptable that it takes an average of 6 years for an accurate diagnosis, or that lupus is the leading cause of death among women aged 15-24 with chronic inflammatory disease.

  • GlobeNewswire

    Exagen Announces Publication of Two Key Studies Validating Clinical Performance of AVISE® Lupus in Patients with Probable SLE and Demonstrating Superior Clinical Utility Compared to Standard Diagnostic Testing

    Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced the publication of two key studies. Collectively, the studies further validate that the information contained in the AVISE® Lupus test positively impacts physician clinical decision-making and demonstrated the patented test and algorithm helped predict those patients with early signs of systemic lupus erythematous (SLE) that are likely to transition to classifiable SLE according to American College of Rheumatology (ACR) criteria.

  • GlobeNewswire

    Exagen Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Exagen Inc. (Nasdaq: XGN),  an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced the closing of its previously announced initial public offering of 4,140,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 540,000 additional shares, at a public offering price of $14.00 per share. Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on September 18, 2019.

  • GlobeNewswire

    Exagen Inc. Announces Pricing of Initial Public Offering

    San Diego, CA, Sept. 18, 2019 -- Exagen Inc. (Nasdaq: XGN),  an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic.

  • Benzinga

    Exagen IPO: What You Need To Know

    A health care company, which develops diagnostic testing products for autoimmune disease, is eyeing a public listing this week. The IPO Terms Vista, California-based Exagen Inc. is planning to offer 3.33 ...